3 completed, 1 active not recruiting. 4 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Completed 3, Active not recruiting 1 |
| Phase 2 | 1 | Active not recruiting 1 |
Follow Primary Mediastinal Lymphoma: new trials by email Literature Review of Primary Mediastinal Lymphoma trials Research Report on Primary Mediastinal Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| CD19-CAR_Lenti T Cells in Pediatric Patients Affected by Relapsed/Refractory CD19+ ALL and DLBCL or PML CD19-CAR_Lenti T cell - Acute Lymphoblastic Leukemia, Diffuse Large B Cell Lymphoma | Phase 1 / Phase 2 | Active not recruiting | Bambino Gesù Hospital and Research Institute | 32 | 2021-03-04 | 2025-12-02 |
| Open-Label, Multi-Center, Two-Part, Ph1 Study to Characterize the PKs of an Intravenous Micro-Dose of [14C]-Tazemetostat (EPZ 6438) and the ADME of an Oral [14C]-Labeled Dose of Tazemetostat in Subjects With B-Cell Lymphomas or Adv Solid Tumors Tazemetostat and [14C] Tazemetostat - Diffuse Large B Cell Lymphoma, Primary Mediastinal Lymphoma | Phase 1 | Completed | Epizyme, Inc. | 3 | 2018-06-20 | 2024-03-22 |
| Ph I Trial of NAM NK Cells and IL-2 for Adult Pts With MM and NHL Nicotinamide Expanded Haploidentical or Mismatched Related Donor Natural Killer Cells - Multiple Myeloma, Non-Hodgkin Lymphoma | Phase 1 | Completed | Masonic Cancer Center, University of Minnesota | 39 | 2017-10-18 | 2022-11-04 |
| Open-Label, Multicenter, Two-Part, Phase 1 Study to Characterize Effects of a Moderate CYP3A Inhibitor on PK of Tazemetostat, Effects of Tazemetostat on PK of CYP2C8 and CYP2C19 Substrates, and Effect of Increased Gastric pH on PK of Tazemetostat in B-cell Lymphoma or Advanced Solid Tumor Patients Tazemetostat, Fluconazole, Omeprazole - Diffuse Large B Cell Lymphoma, Primary Mediastinal Lymphoma | Phase 1 | Completed | Epizyme, Inc. | 32 | 2017-03-27 | 2023-06-26 |
Lymphoma, Large B-Cell, Diffuse (4) · Lymphoma, B-Cell, Marginal Zone (3) · Lymphoma, Mantle-Cell (3) · Lymphoma, Follicular (2) · Lymphoma, Non-Hodgkin (1) · Multiple Myeloma (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1)
Hemic and Lymphatic Diseases (4) · Immune System Diseases (4) · Immunoproliferative Disorders (4) · Lymphatic Diseases (4) · Lymphoma (4) · Lymphoma, B-Cell (4) · Lymphoproliferative Disorders (4) · Neoplasms (4) · Neoplasms by Histologic Type (4) · Lymphoma, Non-Hodgkin (3) · Hematologic Diseases (2) · Blood Protein Disorders (1) · Cardiovascular Diseases (1) · Hemorrhagic Disorders (1) · Hemostatic Disorders (1)
tazemetostat (2) · Fluconazole (1) · Omeprazole (1) · repaglinide (1)
Epizyme, Inc. (2) · Bambino Gesù Hospital and Research Institute (1) · Masonic Cancer Center, University of Minnesota (1)
United States (2) · Italy (1) · United Kingdom (1)
Veronika Bachanova, MD, PhD (1)
2016 (1)